China’s Regulator Accepts Amgen’s Sotorasib for Breakthrough Therapy Designation as a First Milestone
Amgen, a leading global biotech company based in Southern California reported a first—the first time it has successfully achieved Breakthrough […]
Asan Medical Center Reports on Promising Results of Lazertinib in Patients with Non-Small Cell Lung Cancer
Yuhan Corp reports that it made three poster presentations at the virtual meeting of the American Society of Clinical Oncology […]
Sanofi & Regeneron Phase III Lung Cancer Drug Trial Stopped Early Due to Significant Improvement in Overall Survival
Although Sanofi and Regeneron are not in the current PD-1/PD-L1 market mix they are scrambling to be with Libtayo (cemiplimab) […]
Flinders University Investigators Find High BMI Actually Helps Cancer Immunotherapy Patients
Medical research has established that a high Body Mass Index (BMI) adversely impacts one’s risk for obesity, diabetes, cardiovascular, and […]
Dr. Lyudmila Bazhenova, MD & Immuno-Oncology Clinical Investigator Discusses Adverse Events
Dr. Lyudmila Bazhenova, professor of Medicine and thoracic oncologist with the University of California San Diego, and active principal investigator in […]
Vaccitech Oncology Limited Enters Collaboration with Cancer Research UK to Fund a Phase I/IIa Clinical Trial as First-Line NSCLC Therapy
Vaccitech Ltd announced today, December 18th, 2019, that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology […]
Clinical Trials Lead to New Standard of Care for Lung Cancer Patients
Clinical trials results have contributed to a new standard of care for lung cancer patients. The results from several of the […]
Investigational Drug Shows Promise in Patients with RET-Altered Cancers
Patients with RET-fusion-positive non-small cell lung cancer (NSCLC) had a high response to LOXO-292 (selpercatinib), according to findings from the […]
Leading KRAS Inhibitor Candidate for Patients with Lung & Colon Cancer, MRTX849 Producing Positive Data in Phase I Trial
In a Phase 1/2 trial MRTX849, an investigational KRAS G12C inhibitor has demonstrated clinical activity, including objective responses in patients […]
OncLive Peer Exchange Provides Perspective on How the Latest Research from the World Conference for Lung Cancer and the ESMO Annual Meetings Translate to Patient Care and Clinical Practice
Suresh S. Ramalingam, MD, FASCO, Winship Canter Institute of Emery University, leads the discussion on the impact of overall survival […]
